WO2003092622A3 - Carvedilol monocitrate monohydrate - Google Patents

Carvedilol monocitrate monohydrate Download PDF

Info

Publication number
WO2003092622A3
WO2003092622A3 PCT/US2003/013832 US0313832W WO03092622A3 WO 2003092622 A3 WO2003092622 A3 WO 2003092622A3 US 0313832 W US0313832 W US 0313832W WO 03092622 A3 WO03092622 A3 WO 03092622A3
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
monocitrate monohydrate
carvedilol monocitrate
monohydrate
angina
Prior art date
Application number
PCT/US2003/013832
Other languages
French (fr)
Other versions
WO2003092622A2 (en
Inventor
Wei Chen
Choon K Oh
Li-Jen J Ping
Paul G Spoors
Original Assignee
Sb Pharmco Inc
Wei Chen
Choon K Oh
Li-Jen J Ping
Paul G Spoors
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sb Pharmco Inc, Wei Chen, Choon K Oh, Li-Jen J Ping, Paul G Spoors filed Critical Sb Pharmco Inc
Priority to AU2003231283A priority Critical patent/AU2003231283A1/en
Priority to US10/512,628 priority patent/US20050148779A1/en
Priority to EP03724421A priority patent/EP1499310A4/en
Priority to CA002483054A priority patent/CA2483054A1/en
Priority to JP2004500807A priority patent/JP2006500320A/en
Publication of WO2003092622A2 publication Critical patent/WO2003092622A2/en
Publication of WO2003092622A3 publication Critical patent/WO2003092622A3/en
Priority to US11/962,163 priority patent/US20080096951A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

This invention relates to carvedilol monocitrate monohydrate, compositions containing this salt of carvedilol and methods of using this compound to treat hypertension, congestive heart failure and angina.
PCT/US2003/013832 2002-04-30 2003-04-30 Carvedilol monocitrate monohydrate WO2003092622A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003231283A AU2003231283A1 (en) 2002-04-30 2003-04-30 Carvedilol monocitrate monohydrate
US10/512,628 US20050148779A1 (en) 2002-04-30 2003-04-30 Carvedilol monocitrate monohydrate
EP03724421A EP1499310A4 (en) 2002-04-30 2003-04-30 Carvedilol monocitrate monohydrate
CA002483054A CA2483054A1 (en) 2002-04-30 2003-04-30 Carvedilol monocitrate monohydrate
JP2004500807A JP2006500320A (en) 2002-04-30 2003-04-30 Carvedilol monocitrate monohydrate
US11/962,163 US20080096951A1 (en) 2002-04-30 2007-12-21 Carvedilol Monocitrate Monohydrate

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37659902P 2002-04-30 2002-04-30
US60/376,599 2002-04-30
US38328702P 2002-05-23 2002-05-23
US60/383,287 2002-05-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/962,163 Continuation US20080096951A1 (en) 2002-04-30 2007-12-21 Carvedilol Monocitrate Monohydrate

Publications (2)

Publication Number Publication Date
WO2003092622A2 WO2003092622A2 (en) 2003-11-13
WO2003092622A3 true WO2003092622A3 (en) 2004-07-29

Family

ID=29406763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013832 WO2003092622A2 (en) 2002-04-30 2003-04-30 Carvedilol monocitrate monohydrate

Country Status (6)

Country Link
US (2) US20050148779A1 (en)
EP (1) EP1499310A4 (en)
JP (1) JP2006500320A (en)
AU (1) AU2003231283A1 (en)
CA (1) CA2483054A1 (en)
WO (1) WO2003092622A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
AU2003248746B2 (en) * 2002-06-27 2009-01-08 Smithkline Beecham (Cork) Limited Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
CA2492084A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
JP5072364B2 (en) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド Carvedilol free base, carvedilol salt, anhydrous form or solvate thereof, corresponding pharmaceutical composition, controlled release formulation and treatment or delivery method
EP2195292B1 (en) * 2007-08-21 2013-10-02 Lupin Ltd. Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020143045A1 (en) * 2000-06-28 2002-10-03 Jean Hildesheim Carvedilol

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (en) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh NEW CARBAZOLYL- (4) -OXY-PROPANOLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3319027A1 (en) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim METHOD FOR PRODUCING OPTICALLY ACTIVE CARBAZOL DERIVATIVES, NEW R- AND S-CARBAZOL DERIVATIVES, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US5405863A (en) * 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US20010011099A1 (en) * 1995-05-30 2001-08-02 Smithkline Beecham Corporation Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds
JP2001504804A (en) * 1996-08-23 2001-04-10 ベーリンガー・マンハイム・ファーマシューティカルズ・コーポレイション−スミスクライン・ベックマン・コーポレイション・リミテッド・パートナーシップ・ナンバー１ Method for inhibiting FAS expression
JP2002512591A (en) * 1996-10-09 2002-04-23 ベーリンガー・マンハイム・ファーマシューティカルズ・コーポレイション―スミスクライン・ビーチャム・コーポレイション・リミテッド・パートナーシップ・ナンバー１ Inhibition of stress-activated protein kinases
EP0893440A1 (en) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
US6730326B2 (en) * 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
US6664284B2 (en) * 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
PE20001302A1 (en) * 1998-11-27 2000-11-30 Hoffmann La Roche PREPARATIONS OF A PHARMACEUTICAL COMBINATION CONTAINING CARVEDILOL AND HYDROCHLOROTHIAZIDE
US6515010B1 (en) * 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
DE60105996T2 (en) * 2000-04-03 2006-03-09 F. Hoffmann-La Roche Ag CONCENTRATED SOLUTIONS OF CARVEDILOL
EP1385509A4 (en) * 2001-04-02 2004-06-30 Smithkline Beecham Corp Method of treatment
IN191028B (en) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
ATE381924T1 (en) * 2001-09-21 2008-01-15 Egalet As SOLID DISPERSIONS WITH CONTROLLED RELEASE OF CARVEDILOL
WO2003028649A2 (en) * 2001-10-02 2003-04-10 Smithkline Beecham Corporation Novel composition of carvedilol
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
JP2005515226A (en) * 2002-01-15 2005-05-26 テバ ファーマシューティカル インダストリーズ リミティド Crystalline solids of carvedilol and methods for preparing them
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
CA2484624A1 (en) * 2002-05-03 2003-11-13 Smithkline Beecham Pharmco Puerto Rico, Inc. Carvedilol pharmasolve solvate
AU2003248746B2 (en) * 2002-06-27 2009-01-08 Smithkline Beecham (Cork) Limited Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
CA2492084A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
US20040152756A1 (en) * 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP5072364B2 (en) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド Carvedilol free base, carvedilol salt, anhydrous form or solvate thereof, corresponding pharmaceutical composition, controlled release formulation and treatment or delivery method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020143045A1 (en) * 2000-06-28 2002-10-03 Jean Hildesheim Carvedilol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1499310A4 *

Also Published As

Publication number Publication date
US20050148779A1 (en) 2005-07-07
AU2003231283A1 (en) 2003-11-17
JP2006500320A (en) 2006-01-05
AU2003231283A8 (en) 2003-11-17
EP1499310A4 (en) 2005-12-07
WO2003092622A2 (en) 2003-11-13
US20080096951A1 (en) 2008-04-24
CA2483054A1 (en) 2003-11-13
EP1499310A2 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
WO2004002419A3 (en) Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
WO2004064730A3 (en) Compounds, compositions and methods
JO2481B1 (en) Fluoro substituted cycloalkanoindoles, compositions containing such compou- nds and methods of treatment.
MY144470A (en) Compounds, compositions and methods
WO2004058176A3 (en) Acyclic pyrazole compounds
TW200510407A (en) Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
PL1682530T3 (en) Pyrrole substituted indoles as inhibitors of pai-1
WO2004004657A3 (en) Hiv integrase inhibitors
EP1605752A4 (en) Compounds, compositions and methods
WO2004032852A3 (en) Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
NO20060417L (en) Process for Preparation of 1-Octene from Stack-C4
WO2005051325A3 (en) Carvedilol compositions methods of treatment and delivery
WO2002065834A3 (en) Novel formulations of carvedilol
TW200508226A (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
UA85394C2 (en) Substituted quinolines as protein tyrosine kinase enzyme inhibitors
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
IL162052A (en) Indole compounds as inhibitors of cytosolic phospholipase a2, methods of preparation and uses thereof
WO2003092622A3 (en) Carvedilol monocitrate monohydrate
WO2004108086A3 (en) HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE)
WO2005018573A3 (en) 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
WO2004032908A3 (en) Method of inhibiting angiogenesis
MXPA05012437A (en) Compositions, devices and methods for stabilizing and increasing the efficacy of halogen dioxide solutions.
GEP20094604B (en) NEW ASSOCIATION OF A SINUS NODE if CURRENT INHIBITOR AND AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
WO2006050457A3 (en) Methods and compositions for treating chronic lymphocytic leukemia
WO2004002472A8 (en) Carvedilol hydrobromide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2483054

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10512628

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004500807

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003724421

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003724421

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003724421

Country of ref document: EP